Clinical Read2026-07-13

Bempikibart - (SIGNAL-AA)

Q32 Bio Inc.QTTB
Indication
Alopecia areata (AA)
Stage
phase2
Event
Topline Data
Details

July 10, 2026: Q32 Bio Inc. (NASDAQ: QTTB) announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart (ADX-914), a fully human anti-IL-7Rα antibody, in patients with severe or very severe alopecia areata. The data will be released Monday, July 13, 2026, followed by a conference call and webcast at 8:00 a.m. ET to discuss the results.